Last reviewed · How we verify
Chemotherapy and antibodies
A combination therapy using chemotherapy agents alongside monoclonal antibodies to target and destroy cancer cells while enhancing immune recognition.
A combination therapy using chemotherapy agents alongside monoclonal antibodies to target and destroy cancer cells while enhancing immune recognition. Used for Pediatric cancers (specific indication under investigation in Phase 3 trial).
At a glance
| Generic name | Chemotherapy and antibodies |
|---|---|
| Also known as | Graft versus host disease, Cyclophosphamide, Fludarabine, Thiotepa, Melphalan |
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Combination chemotherapy and monoclonal antibody therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach combines traditional chemotherapy drugs with antibody-based immunotherapy to attack pediatric cancers through dual mechanisms: direct cytotoxic effects from chemotherapy and immune-mediated tumor cell killing via antibodies. The antibodies may target tumor-associated antigens or immune checkpoints to enhance the body's natural anti-cancer response.
Approved indications
- Pediatric cancers (specific indication under investigation in Phase 3 trial)
Common side effects
- Myelosuppression
- Infection
- Nausea and vomiting
- Infusion reactions
- Immunotoxicity
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy and antibodies CI brief — competitive landscape report
- Chemotherapy and antibodies updates RSS · CI watch RSS
- St. Jude Children's Research Hospital portfolio CI